| Contents per vial | Ipamorelin 5 mg + CJC-1295 5 mg (10mg) |
|---|---|
| Form | Lyophilized powder |
| Packaging | Sealed glass vial |
| Purity | High purity, research grade |
| Storage | 2–8 °C, keep dry and protect from light |
| Molecular formula | Blend |
| Molecular weight | Blend |
| Sequence or structure | Ipamorelin: Aib–His–D-2-Nal–D-Phe–Lys–NH2 |
| CJC without DAC | Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Gln–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Leu–Ser–Arg–NH2 |
| CAS | Ipamorelin: 170851-70-4; CJC without DAC: 446036-97-1 |
| Intended use | For laboratory research only |
About this product
Ipamorelin + CJC-1295 is a two-component research formulation containing 5 mg of ipamorelin and 5 mg of CJC-1295. It combines the ghrelin receptor agonist GHS-R1a with a GHRH analog, thus allowing the investigation of two distinct signaling pathways regulating growth hormone secretion.
What is IPAMORELIN + CJC-1295?
IPAMORELIN + CJC-1295 is a combination of two synthetic peptides intended for controlled laboratory investigation of the growth hormone-IGF-1 axis. Ipamorelin activates the GHS-R1a receptor, while CJC-1295 acts on the GHRH receptor.
Mechanism of action under investigation
Ipamorelin promotes growth hormone secretion via the ghrelin receptor GHS-R1a and intracellular calcium-coupled signaling. CJC-1295 mimics GHRH and activates the GHRH receptor via the cAMP pathway. The combination is being investigated for possible simultaneous stimulation of somatotropic cells by two different receptor mechanisms.
MAIN AREAS OF RESEARCH
• Growth hormone secretion: Laboratory research can compare the amplitude and time course of the GH response after individual components and after their combination.
• GH/IGF-1 axis: Concentrations of growth hormone, IGF-1 and other biomarkers that describe the activation of the hormonal axis in a defined experimental model are monitored.
• Receptor interplay: Ipamorelin and CJC-1295 use different receptors and intracellular signals. Therefore, research focuses on whether the joint response is additive or whether a measurable interaction occurs between the two pathways.
• Signal pulsatility and duration: The time profile depends mainly on the exact form of CJC-1295. The variant with DAC has a different duration than the variant without DAC, therefore the results cannot be correctly interpreted without confirming the identity of the component.
Research findings to date
Ipamorelin alone has been investigated as a selective growth hormone secretagogue, while CJC-1295 is being investigated as a GHRH analogue. Both agents can affect the GH/IGF-1 axis, but use different receptors.
